{"id":"NCT01204775","sponsor":"AstraZeneca","briefTitle":"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin (BMS-477118) as Monotherapy in Pediatric Patients With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2016-04","completion":"2016-04","firstPosted":"2010-09-17","resultsPosted":"2017-04-18","lastUpdate":"2017-04-18"},"enrollment":26,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Saxagliptin","otherNames":["BMS-477118","Onglyza"]},{"type":"DRUG","name":"Placebo (Saxagliptin)","otherNames":[]},{"type":"DRUG","name":"Metformin IR","otherNames":[]},{"type":"DRUG","name":"Placebo (Metformin)","otherNames":[]},{"type":"DRUG","name":"Metformin (Active Rescue)","otherNames":[]}],"arms":[{"label":"Saxagliptin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy, safety, tolerability, of Saxagliptin in pediatric patients with type 2 diabetes.","primaryOutcome":{"measure":"Mean Change in HbA1c From Baseline to Week 16","timeFrame":"16 week short term treatment period","effectByArm":[{"arm":"Saxagliptin","deltaMin":-0.7,"sd":0.83},{"arm":"Placebo","deltaMin":0.6,"sd":1.53}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":null},"locations":{"siteCount":16,"countries":["United States","Russia","South Africa","Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":4},"commonTop":["OROPHARYNGEAL PAIN","COUGH","Headache","UPPER RESPIRATORY TRACT INFECTION","ACNE"]}}